Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 198

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Progress towards elimination goals for viral hepatitis

Open access
Cox, Andrea L., El-Sayed, Manal H., Kao, Jia-Horng, Lazarus, Jeffrey V., Lemoine, Maud, Lok, Anna S., Zoulim, Fabien · 2020 · Nature Reviews Gastroenterology & Hepatology

Abstract

The global burden of viral hepatitis is substantial; in terms of mortality, hepatitis B virus and hepatitis C virus infections are on a par with HIV, malaria and tuberculosis, among the top four global infectious diseases. In 2016, the 194 Member States of the World Health Organization committed to eliminating viral hepatitis as a public health threat by 2030, with a particular focus on hepatitis B virus and hepatitis C virus infection. With only 10 years to go until the 2030 deadline is reached, and although much progress has been made towards elimination, there are still some important gaps in terms of policy and progress. In this Viewpoint, we asked a selection of scientists and clinicians working in the viral hepatitis field for their opinions on whether elimination of viral hepatitis by 2030 is feasible, what the key areas of progress are and what the focus for the next 10 years and beyond should be for viral hepatitis elimination. Viral hepatitis is a global public health problem. In this Viewpoint, we asked a selection of scientists and clinicians working in the viral hepatitis field to provide their opinions on progress and pitfalls towards the 2030 viral hepatitis elimination goals. Andrea L. Cox is currently a Professor of Medicine, Oncology, and Immunology at The Johns Hopkins University School of Medicine, USA. Her research and clinical interests focus on hepatitis C virus, hepatitis B virus and HIV, including mechanisms through which these chronic viral infections stimulate and evade immune responses. Manal H. El-Sayed is Professor of Paediatrics and director of the Clinical Research Centre at the Faculty of Medicine, Ain Shams University. She is a founding member of the Egyptian National Committee for Control of Viral Hepatitis since 2006. She is the secretary general of the Egyptian Liver Care Society (NGO) and board member of the EASL International Liver Foundation. Jia-Horng Kao is the Chair Professor of the Graduate Institute of Clinical Medicine at the National Taiwan University, Taipei, Taiwan. He has published more than 550 articles on the prevention, natural history, molecular virology, pathogenesis and treatment of chronic viral hepatitis and liver cancer. He is currently the Steering Council member of The Asian Pacific Association for the Study of the Liver (APASL). Jeffrey V. Lazarus is head of the Health Systems and Infectious Diseases team at the Barcelona Institute for Global Health (ISGlobal) and an Associate Professor at the Faculty of Medicine, University of Barcelona, Spain. He is Vice-Chairman of the board of the EASL International Liver Foundation, where he leads the work on the microelimination of hepatitis C. Maud Lemoine is Professor and Honorary Consultant in Hepatology at Imperial College London, UK. Her research interests are mainly related to viral hepatitis in resource-limited countries, where she developed expertise on screening and management of patients with viral hepatitis. She is the head of the PROLIFICA (Prevention of Liver Fibrosis and Cancer in Africa) programme and the chief investigator and co-investigator of several studies and interventions on the prevention and management of viral hepatitis B and C in West and East Africa. Anna S. Lok is a Professor of Internal Medicine, Director of Clinical Hepatology, and Assistant Dean for Clinical Research at the University of Michigan, USA. She has published more than 550 articles on viral hepatitis and liver diseases including five editions of the American Association for the Study of Liver Diseases guidelines on hepatitis B and the first edition of the World Health Organization guidelines on hepatitis B. Fabien Zoulim is Professor of Medicine at Lyon University, Head of the Hepatology Department at the Hospices Civils de Lyon, and Head of the Viral Hepatitis Research Laboratory at INSERM U1052, France. He is currently coordinating the ANRS “HBV cure” programme in France and the “IP-cure-B” project funded by the EU H2020 work programme. He co-founded the International Coalition to Eliminate HBV (ICE-HBV).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41575-020-0332-6

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 198

Metadata

Authors
Cox, A. L., El-Sayed, M. H., Kao, J.-H., Lazarus, J. V., Lemoine, M., Lok, A. S., & Zoulim, F.
Venue
Nature Reviews Gastroenterology & Hepatology
Published
2020-07-23
Volume
17
Issue
9
Pages
533-542
ISSN
  • 1759-5045 (ISSN-L)
  • 1759-5053
OpenAlex
W3043984268
Cited by
198
References
1
FWCI
5.27
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progress towards elimination goals for viral hepatitis. https://app.cochat.ai/papers/10.1038/s41575-020-0332-6
The paper
Cox, A. L., El-Sayed, M. H., Kao, J.-H., Lazarus, J. V., Lemoine, M., Lok, A. S., & Zoulim, F. (2020). Progress towards elimination goals for viral hepatitis. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-020-0332-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.